Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer

This prospective randomised trial assigned postmenopausal women with HR-positive breast cancer who had received 5 years of adjuvant endocrine therapy (n=3484) to receive either additional 2 or 5 years of anastrozole. After a median follow-up of 118 months, disease progression or death occurred in 335 women in each treatment group with no differences in disease free survival (HR, 0.99; 95% CI; 0.85 to 1.15; p=0.9). No between-group differences occurred in secondary endpoints including overall survival, contralateral breast cancer, and second primary breast cancer. However, the risk of clinical bone fracture was higher in the 5-year group (HR, 1.35; 95% CI; 1.00 to 1.84).

Classifications: Adjuvant & Neoadjuvant Treatment

Keywords: Endocrine Therapy